Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action.
- Resource Type
- Article
- Authors
- Nelson, Nathaniel C.; Kogan, Rebecca; Condos, Rany; Hena, Kerry M.
- Source
- Journal of Clinical Medicine. Jan2024, Vol. 13 Issue 1, p15. 20p.
- Subject
- *SARCOIDOSIS
*PATIENT experience
*REFRACTORY materials
*DISEASE progression
*PATIENTS' attitudes
- Language
- ISSN
- 2077-0383
Sarcoidosis is a systemic disease with heterogenous clinical phenotypes characterized by non-necrotizing granuloma formation in affected organs. Most disease either remits spontaneously or responds to corticosteroids and second-line disease-modifying therapies. These medications are associated with numerous toxicities that can significantly impact patient quality-of-life and often limit their long-term use. Additionally, a minority of patients experience chronic, progressive disease that proves refractory to standard treatments. To date, there are limited data to guide the selection of alternative third-line medications for these patients. This review will outline the pathobiological rationale behind current and emerging therapeutic agents for refractory or drug-intolerant sarcoidosis and summarize the existing clinical evidence in support of their use. [ABSTRACT FROM AUTHOR]